About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARWR - Arrowhead Pharmaceut...| Previous Close | $45.15 | Open | $45.28 |
| Volume | 728K | Market Cap | 4.595B |
| Yield | Last Dividend |
| Arrowhead Pharmaceuticals to Host Key Op... | 07/09/20 |
| Arrowhead Pharma will host a KOL webinar on ARO-ENaC for treatment of cystic fibrosis | |
| Arrowhead Pharmaceuticals to Participate... | 05/28/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at Jefferies and Goldman Sachs healthcare conferences in June 2020 | |
| Arrowhead Pharmaceuticals Is Likely to S... | 05/22/20 |
| I would look for further sideways trading on ARWR???.ARWR | |
| Arrowhead Pharmaceuticals, Inc (ARWR) Q2... | 05/08/20 |
| ARWR earnings call for the period ending March 31, 2020. | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 05/07/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal Q2 2020 earnings | |
| Arrowhead Pharmaceuticals to Participate... | 05/01/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will present at upcoming May 2020 investor conferences | |
| Arrowhead Pharmaceuticals Announces Reti... | 05/01/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Bruce Given retires from Arrowhead Pharmaceuticals | |
| Arrowhead Pharmaceuticals to Webcast Fis... | 04/22/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast fiscal 2020 second quarter earnings on May 7, 2020 | |
| Pre & Post COVID-19 Market Estimates-Glo... | 04/22/20 |
| LONDON--(BUSINESS WIRE)-- #OligonucleotideTherapeuticsMarket--The oligonucleotide therapeutics market size has the potential to grow by USD 901.18 mil... | |
| Arrowhead Pharmaceuticals Files for Regu... | 04/10/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files to begin Phase 1/2a study of ARO-ENaC, RNAi therapeutic for Cystic Fibrosis | |
| Arrowhead Pharmaceuticals Announces Prec... | 03/17/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead provides update related to COVID-19 efforts | |
| Arrowhead Pharmaceuticals to Participate... | 03/02/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will participate in multiple conference presentations in March 2020 | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 02/05/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results | |
| Arrowhead (ARWR) to Report Q1 Earnings: ... | 02/03/20 |
| We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results. | |
| Arrowhead Pharma Investors Should Aim fo... | 12/23/19 |
| ARWR is tightly extended on the upside, so now's time to enjoy your winnings???.ARWR | |
| Arrowhead Pharmaceuticals Doses First Pa... | 12/20/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT | |
| Arrowhead Pharmaceuticals Files for Regu... | 12/16/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files CTA for Phase 1 clinical trial of ARO-HSD, the company???s RNAi therapeutic for alcohol a... | |
| Arrowhead Pharmaceuticals Appoints Maria... | 12/13/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals appointed veteran pharmaceutical industry executive Marianne De Backer, Ph.D., ... | |
| Arrowhead Pharmaceuticals Files IND for ... | 12/11/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell... | |
| Arrowhead Pharmaceuticals Closes Underwr... | 12/06/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million | |
| Arrowhead Pharmaceuticals Announces Pric... | 12/04/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock | |
| Arrowhead Pharmaceuticals Announces Prop... | 12/02/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock | |
| The Daily Biotech Pulse: Tonix Says No S... | 11/27/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) ... | |
| FedEx, Synopsys, Autodesk: 'Mad Money' L... | 11/26/19 |
| Jim Cramer takes a look at FedEx, Synopsys, Autodesk, Grocery Outlet, Arrowhead Pharmaceuticals and more???.SNPS | |
| Cramer's lightning round: I like FedEx a... | 11/26/19 |
| The "Mad Money" host says FedEx is too cheap right now, and he also recommended taking some shares of Arrowhead Pharmaceuticals off the table. | |
| Arrowhead Pharmaceuticals to Participate... | 11/26/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to present at upcoming December 2019 conferences | |
| The Daily Biotech Pulse: ChemoCentryx Tr... | 11/26/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.... | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 11/25/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal year 2019 financial results | |
| The Daily Biotech Pulse: Endo's Cellulit... | 11/20/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) ... | |
| Arrowhead Presents New Clinical Data on ... | 11/18/19 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data at AHA Scientific Sessions 2019 on ARO-ANG3 and ARO-APOC3 RNAi-based cardiometabo... | |
| Strong Buy rating | 05/13/20 |
| RBC Capital initiates coverage with Outperform rating and announces Price Target of $62.00 | |
| Strong Buy rating | 05/08/20 |
| and lowers Price Target from $60.00 to $58.00 | |
| Strong Buy rating | 04/15/20 |
| Cantor Fitzgerald upgrades from Neutral to Overweight rating and announces Price Target of $60.00 | |
| Date | 2020-05-07 (AMC) | Est. (EPS/Rev.) | ($0.11)/ 21.74M |
| Actual (EPS/Rev.) | $-0.20/ $23.53 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Value Investing | Flying Colors | 88.00 % | Subscribe |
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
| Optioneering-W | Sam Allen | 31.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
